Evidence map›Paper›PMID 38116854›Full record

ArticleChembiochem : a European journal of chemical biology2024

Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation.

Xueqing Nie, Yu Zhao, Hua Tang, Zhongrui Zhang, Junzhuo Liao, Chelsi M Almodovar-Rivera, Ramya Sundaresan, Haibo Xie, Le Guo, Bo Wang and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Evolving CRBN ligands enhance the drug-like properties of protein degraders.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Xueqing NieLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Yu ZhaoLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Hua TangLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Zhongrui ZhangDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Junzhuo LiaoLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Chelsi M Almodovar-RiveraLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Ramya SundaresanDepartment of Oncology, UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Haibo XieLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Le GuoLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Bo WangLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Hongqing GuanDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Yongna XingDepartment of Oncology, UW Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Weiping TangLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.ORCID 0000-0002-0039-3196
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Chemistry-Biology Interface Training ProgramT32GM008505 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BLACKWELL, HELEN E. · 1993 to 2023
$9.8M
Chemical Synthesis and Biological Application of Carbohydrates and Glycoconjugates - Admin SupplementR35GM148266 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Weiping Tang · 2023 to 2026
$1.8M
Structural and Cellular Choreography for Decommissioning and Recycling of PP2A HoloenzymesR01GM137090 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI XING, YONGNA · 2021 to 2024
$1.3M
NCI NIH HHS P30 CA014520NIGMS NIH HHS R01 GM137090NIGMS NIH HHS R35 GM148266NIGMS NIH HHS T32 GM008505NIH HHS R01 GM137090NIH HHS R35GM148266
6 · The paper itself

Abstract

Thalidomide, pomalidomide and lenalidomide, collectively referred to as immunomodulatory imide drugs (IMiDs), are frequently employed in proteolysis-targeting chimeras (PROTACs) as cereblon (CRBN) E3 ligase-recruiting ligands. However, their molecular glue properties that co-opt the CRL4

Indexed as

Nuclear ProteinsPeptide HydrolasesPhthalimidesBenzimidazolesImmunomodulating AgentsLigandsProteolysisTranscription FactorsUbiquitin-Protein LigasesBenzimidazolesImmunomodulating AgentsLigandsNuclear ProteinsPeptide HydrolasesPhthalimidesphthalimidineTranscription FactorsUbiquitin-Protein LigasesCRBNIMiDsPROTACTargeted Protein Degradation

Identifiers

PMID38116854
PMCPMC10922875
OpenAlexW4389992353

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.